

Next Science enters into US\$5m unsecured loan facility

Next Science Limited (ASX:NXS) (“Next Science” or “the Company”) today announces that it has entered into a facility agreement with TIGA Trading Pty. Ltd. (the “Lender”, a company associated with the Thorney Investment Group¹) dated 17 July 2024 (Facility Agreement) under which the Lender will provide the Company with a US\$5 million unsecured loan facility (Facility).

Next Science may draw on the Facility to assist with general working capital requirements and for any other corporate purpose of the Company that the Lender approves. The Facility will mature on 17 July 2026.

A summary of the material terms of the Facility is set out in the Appendix to this announcement.

In conjunction with the execution of the Facility Agreement, the parties have signed an option deed under which the Company will issue the Lender with 5 million options at an exercise price of A\$0.42 and with a three-year expiry. These options will be issued from Next Science’s available Placement capacity under ASX Listing Rule 7.1.

Next Science’s CEO and Managing Director I.V. Hall said: “Next Science reviews its funding requirements on an ongoing basis and believes it has sufficient working capital to meet its obligations. However, as flagged at the 1Q FY24 result, the Company has explored funding options to provide a buffer against unexpected financial challenges and the flexibility to respond should investment opportunities arise. The unsecured US\$5m loan facility with Thorney Investment Group provides access to additional capital, if needed, as we continue to transform key elements of the business.”

Approved and authorised for release by the Board of Directors.

Media & Investor Enquiries

Françoise Dixon

Phone: +61 412 292 977

Email: fdixon@nextscience.com

¹ Thorney Investment Group is currently a substantial shareholder in Next Science Limited. Refer to ASX Announcement on 20 September 2023 from Thorney Investment Group. Thorney Investment Group is not a related party of the Company.

Appendix

Key Terms of Loan Facility Agreement & Option Deed

Borrower	Next Science Limited ACN 622 382 549 (Next Science)
Lender	TIGA Trading Pty. Ltd. ACN 118 961 210 (Lender)
Facility Limit	US\$5,000,000
Purpose	To assist with the general working capital requirements and any other corporate purpose of the Company or for any other purpose that the Lender approves.
Utilisation mechanics	Next Science may request a drawing of the Facility on two business days' notice by issuing a utilisation notice to the Lender. A drawing may not be requested sooner than 2 weeks after the most recent utilisation notice.
Term and maturity	17 July 2026
Security	Unsecured loan
Interest	Interest is payable at 12% per annum (Interest Rate) on amounts drawn under the Facility. Interest is payable on repayment on the earlier of the Termination Date and the date the principal outstanding is repaid in full.
Overdue Interest	Next Science must pay interest at the Overdue Rate (being the rate which is 2% higher than the Interest Rate) on any amount which is due and payable under the Facility but which is not paid.
Fee	In lieu of a line fee, Next Science will issue the Lender 5m options over unissued ordinary shares (which represents 1.7% of the total number of ordinary shares on issue at today's date). (See details on the Option terms below).
Options	Each option entitles the holder to subscribe for one ordinary share in Next Science on the exercise of the option. Each option has an exercise price of A\$0.42 and a three-year expiry. The options will not be quoted on the ASX.

NEXT SCIENCE®

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may” and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involved known and unknown risks uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management and could cause Next Science's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.